MicroRNA biomarkers
Search documents
DiamiR Biosciences and Aptorum Group Announce Two Abstracts Accepted for Presentation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2025 Conference
Globenewswire· 2025-11-19 13:00
NEW YORK, NY, NEW HAVEN, CT, and PRINCETON, N.J., Nov. 19, 2025 (GLOBE NEWSWIRE) -- DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, and Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, announce two poster presentations at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference, taking place December 1-4, 2025, in ...